Immunome (IMNM) Payables (2019 - 2026)

Immunome (IMNM) has 8 years of Payables data on file, last reported at $5.5 million in Q1 2026.

• Quarterly Payables fell 39.36% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (down 39.36% YoY) and the FY2025 annual result came in at $3.3 million, down 76.47% from the prior year.
• Payables improved to $5.5 million in Q1 2026, from $3.3 million in the prior quarter.
• In the past five years, Payables ranged from a high of $14.2 million in Q4 2024 to a low of $2.4 million in Q4 2022.
• A 5-year average of $5.2 million and a median of $3.9 million in 2022 frame the typical range for Payables.
• Annual changes were most pronounced in 2024 — Payables jumped 328.54% — and 2025, when it tumbled 76.47%.
• Tracing IMNM's Payables over 5 years: stood at $2.4 million in 2022, then surged by 37.96% to $3.3 million in 2023, then jumped by 328.54% to $14.2 million in 2024, then plunged by 76.47% to $3.3 million in 2025, then soared by 65.74% to $5.5 million in 2026.
• The last three Payables figures came in at $5.5 million (Q1 2026), $3.3 million (Q4 2025), and $6.1 million (Q3 2025), per Business Quant data.